Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure [10]

Gut

Volumn 52, Issue 4, 2003, Pages 614-

  Thabut, D ^a,b   Ratziu, V ^a   Bernard Chabert, B ^a   Poynard, T ^a   Benhamou, Y ^a   Thibault, V ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Service d'Hépato Gastroentérologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; LAMIVUDINE;

ADULT; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; INFLAMMATION; LETTER; LIVER FAILURE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FATAL OUTCOME; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER FAILURE, ACUTE; MIDDLE AGED; PHOSPHONIC ACIDS; SALVAGE THERAPY;

EID: 0345268700     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.4.614     Document Type: Letter

References (10)

1. Benhamou Y, Bochet M, Thibault V, et at. Safety and efficacy of adefovir dipivoxilo in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718-23.
2. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61-8.
3. Atkins M, Gray DF. Lamivudine resistance in chronic hepatitis B. J Hepatol 1998;28:169.
4. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seraconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
5. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatalogy 1999;30:567-72.
6. de Man RA, Bartholomeusz AI, Niesters HG, et al. The sequential occurrence of viral mutations in a Fiver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol 1998;29:669-75.
7. Peters MG, Singer G, Howard T, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999;68:1912-4.
8. Starkel P, Horsmans Y, Geubel A, et al. Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure due to the emergence of a hepotitis B YMDD escape mutant virus. J Hepatol 2001;35:679-81.
9. Thabut D, Thibault V, Benhamou Y, et al. Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in a HIV-infected patient. AIDS 2001;15:2463.
10. Kim JW, Lee HS, Woo GH, et al. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis 2001;33:403-5.